Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,034 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,609 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (799)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04326764 | Panobinostat Maintenance After HSCT fo High-risk AML and MDS | terminated | Phase 3 | 52 | Goethe UniversityOTHER | 2 | Feb 16, 2023 | clinicaltrials |
| NCT02172872 | "InDACtion" vs "3+7" Induction in AML | unknown | Phase 3 | 606 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Feb 15, 2023 | clinicaltrials |
| NCT04095858 |
| Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)(CATHY) |
| terminated |
| Phase 3 |
| 11 |
| Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY |
| 1 |
| Feb 8, 2023 |
| clinicaltrials |
| NCT00075816 | Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) | completed | Phase 3 | 551 | Medical College of WisconsinOTHER | 2 | Jan 4, 2023 | clinicaltrials |
| NCT00406393 | Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) | completed | Phase 3 | 304 | Medical College of WisconsinOTHER | 2 | Jan 4, 2023 | clinicaltrials |
| NCT00866918 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia | completed | Phase 3 | 106 | Children's Oncology GroupNETWORK | 3 | Oct 25, 2022 | clinicaltrials |
| NCT05404906 | AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission | recruiting | Phase 2 / Phase 3 | 124 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05311943 | Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. | unknown | Phase 3 | 40 | Shenzhen Second People's HospitalOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04093505 | Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)(GnG) | terminated | Phase 3 | 28 | University Hospital HeidelbergOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT01303796 | A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia(SEAMLESS) | completed | Phase 3 | 482 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 12 | Jun 22, 2022 | clinicaltrials |
| NCT04676243 | Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML(Q-SOC) | withdrawn | Phase 3 | 0 | University Hospital HeidelbergOTHER | 0 | May 25, 2022 | clinicaltrials |
| NCT02999854 | Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer(HATCY) | terminated | Phase 3 | 63 | Kiadis PharmaINDUSTRY | 13 | May 24, 2022 | clinicaltrials |
| NCT05382390 | Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial | unknown | Phase 3 | 130 | Huihan WangOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT00450450 | Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases | completed | Phase 3 | 27 | Children's Oncology GroupNETWORK | 1 | Apr 28, 2022 | clinicaltrials |
| NCT01387763 | A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms(DALIAH) | completed | Phase 3 | 202 | Thomas Stauffer LarsenOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT02927938 | Leukemia Stem Cell Detection in Acute Myeloid Leukemia | terminated | Phase 3 | 18 | Wake Forest University Health SciencesOTHER | 1 | Apr 21, 2022 | clinicaltrials |
| NCT02566395 | Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies | completed | Phase 3 | 10 | Northwell HealthOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT04490707 | Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML | unknown | Phase 3 | 60 | Ge ZhengOTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT03942094 | Nilotinib for First-line Newly Diagnosed CML-CP Patients | unknown | Phase 3 | 100 | Shenzhen Second People's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT03151408 | An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia | terminated | Phase 3 | 406 | Helsinn Healthcare SAINDUSTRY | 16 | Mar 10, 2022 | clinicaltrials |
| NCT04174612 | AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance(AMELIORATE) | unknown | Phase 3 | 172 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT00369317 | Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 3 | 205 | Children's Oncology GroupNETWORK | 4 | Jan 28, 2022 | clinicaltrials |
| NCT05175508 | Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS | unknown | Phase 2 / Phase 3 | 180 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT04722952 | PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML | unknown | Phase 3 | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT01597778 | Double Cord Versus Haploidentical (BMT CTN 1101) | completed | Phase 3 | 368 | Medical College of WisconsinOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT02627677 | A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia(OPTIC-2L) | terminated | Phase 3 | 44 | Ariad PharmaceuticalsINDUSTRY | 1 | Nov 26, 2021 | clinicaltrials |
| NCT02214407 | Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML(GFM-DAC-CMML) | completed | Phase 3 | 170 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Nov 19, 2021 | clinicaltrials |
| NCT02055781 | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia(PAC326) | terminated | Phase 3 | 311 | CTI BioPharmaINDUSTRY | 12 | Nov 18, 2021 | clinicaltrials |
| NCT01596114 | European Stop Tyrosine Kinase Inhibitor Study(EURO-SKI) | completed | Phase 3 | 868 | European LeukemiaNetNETWORK | 10 | Nov 5, 2021 | clinicaltrials |
| NCT04716114 | A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated(ALIVE) | unknown | Phase 3 | 315 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 2, 2021 | clinicaltrials |
| NCT00412360 | Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) | completed | Phase 3 | 224 | Medical College of WisconsinOTHER | 3 | Oct 28, 2021 | clinicaltrials |
| NCT00766779 | HCT Versus CT in Elderly AML | terminated | Phase 3 | 126 | European Society for Blood and Marrow TransplantationNETWORK | 7 | Oct 14, 2021 | clinicaltrials |
| NCT02298166 | Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations | terminated | Phase 3 | 9 | University of UlmOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT03257241 | A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old(PALG-AML1/2016) | unknown | Phase 3 | 582 | Polish Adult Leukemia GroupOTHER | 2 | Oct 1, 2021 | clinicaltrials |
| NCT03887156 | Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft(Predictor2) | unknown | Phase 2 / Phase 3 | 227 | Assistance Publique - Hôpitaux de ParisOTHER | 3 | Sep 28, 2021 | clinicaltrials |
| NCT02899169 | Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)(APL16) | unknown | Phase 3 | 110 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT00003816 | Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer | completed | Phase 2 / Phase 3 | 361 | Roswell Park Cancer InstituteOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT00703820 | Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 3 | 324 | St. Jude Children's Research HospitalOTHER | 2 | Aug 10, 2021 | clinicaltrials |
| NCT03825887 | Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients(PCA) | completed | Phase 3 | 80 | Children's Cancer Hospital Egypt 57357OTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT02038036 | Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.(RESPONSE-2) | completed | Phase 3 | 149 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 20, 2021 | clinicaltrials |
| NCT01817075 | Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant | completed | Phase 3 | 177 | Children's Oncology GroupNETWORK | 3 | Jun 22, 2021 | clinicaltrials |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | terminated | Phase 2 / Phase 3 | 40 | Kiadis PharmaINDUSTRY | 7 | Jun 14, 2021 | clinicaltrials |
| NCT02218047 | AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.(CONTI-PV) | completed | Phase 3 | 170 | AOP Orphan Pharmaceuticals AGINDUSTRY | 12 | Jun 1, 2021 | clinicaltrials |
| NCT03066466 | Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT | withdrawn | Phase 3 | 0 | Loyola UniversityOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT02707393 | Allogeneic Stem Cell Transplantation for Children With CML | completed | Phase 2 / Phase 3 | 13 | St. Anna KinderkrebsforschungOTHER | 3 | Apr 15, 2021 | clinicaltrials |
| NCT01307579 | Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia | completed | Phase 3 | 517 | Children's Oncology GroupNETWORK | 3 | Mar 30, 2021 | clinicaltrials |
| NCT03800095 | Early Palliative Care for Patients With Haematological Malignancies(CALVI) | unknown | Phase 3 | 140 | University Hospital, Clermont-FerrandOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT00606723 | Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML | completed | Phase 3 | 154 | Hannover Medical SchoolOTHER | 3 | Mar 22, 2021 | clinicaltrials |
| NCT02039726 | (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive | completed | Phase 3 | 367 | Daiichi SankyoINDUSTRY | 19 | Feb 24, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Feb 16, 2023source: clinicaltrials